CompletedNCT04624243

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

This study is completed. It focuses on schizophrenia and currently lists study information in Bulgaria, Croatia, Japan, Latvia, Poland, Romania, Russian Federation, Serbia, South Korea, Taiwan, Ukraine, and the United States.

SchizophreniaOtherFrom 18 Years to 55 Years

In plain English

Key information made simple

This study exists to see whether the medication MK-8189 can play a useful role in care. Researchers are trying to understand how people respond to the medication MK-8189 in practice and what may need to be adjusted. For people living with Schizophrenia, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could lead to earlier recognition and more informed decisions later on. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Pillar Clinical Research ( Site 1047) in Bentonville, Woodland International Research Group, LLC ( Site 1002) in Little Rock, and Woodland Research Northwest, LLC ( Site 1036) in Rogers. Participation appears to involve using a digital tool or support program and giving feedback through check-ins or assessments. The main fit is usually being able to follow the planned visits or tasks and matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Public study data

Key study information

Condition: Schizophrenia
Study status: Completed
Sponsor / lead affiliation: Merck Sharp & Dohme LLC
Location / country: Bulgaria, Croatia, Japan, Latvia, Poland, Romania, Russian Federation, Serbia, South Korea, Taiwan, Ukraine, United States
Registry: ClinicalTrials.gov

Why this study may matter

This study may matter because it adds public evidence around schizophrenia. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: NCT04624243. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may help clarify how this condition is measured or understood.

It requires regular follow-up, often through questionnaires or interviews.

Requires travel, with in-person participation in Bulgaria.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor: Merck Sharp & Dohme LLC
Sponsor type: Other organization
Main activity: digital app or tool
Intervention: Not available
Time commitment: long follow-up or multiple visits
Study phase: Not available
Enrollment: Not available
Recruitment status: Completed
Source: Official registry link

FAQ

Questions about this study

What is Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)?

This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Merck Sharp & Dohme LLC. Based on the sponsor name or official registry information, it appears to be another type of organization. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve digital app or tool, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.